Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21FN2O4.C6H14N4O2 |
| Molecular Weight | 534.5804 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCCNC(N)=N)C(O)=O.C[C@H]1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCC(O)CC4
InChI
InChIKey=WIFOPRFVQIVWTB-YBVIJTQESA-N
InChI=1S/C19H21FN2O4.C6H14N4O2/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21;7-4(5(11)12)2-1-3-10-6(8)9/h8-11,23H,2-7H2,1H3,(H,25,26);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t10-;4-/m00/s1
| Molecular Formula | C6H14N4O2 |
| Molecular Weight | 174.201 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C19H21FN2O4 |
| Molecular Weight | 360.3794 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Levonadifloxacin is the S-(-) isomer of the benzoquinolizine fluoroquinolone nadifloxacin and is two- to four-fold more active than the racemic mixture. Levonadifloxacin is a potent antibacterial agent against Gram-positive bacteria especially against methicillin resistance Staphylococcus aureus. It also possesses potent bactericidal activity against other resistant variants like quinolone-resistant Staphylococcus aureus, vancomycin and glycopeptide intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Intravenous dosage form developed to treat complicated skin and skin structure infections and has recently completed Phase III studies in India and Phase I studies in USA.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Activity of the new quinolone WCK 771 against pneumococci. | 2005 Jan |
|
| Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. | 2005 Oct |
|
| The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. | 2006 Nov |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:20:29 GMT 2023
by
admin
on
Sat Dec 16 18:20:29 GMT 2023
|
| Record UNII |
U2RV55F5O0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
U2RV55F5O0
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY | |||
|
306748-89-0
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY | |||
|
9850037
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY | |||
|
DTXSID60184714
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |